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Reviewer: 1
Comments to the Author
I think the authors for their consideration of the previous comments and how they've 
addressed the issues, and am happy to see this go through with one thing to be resolved. 
Sorry to be that guy here, but I think there's a misunderstanding on MDC and MCID.
I think you have to consider these as additive, not independent as you've inferred from your 
figure. In essence, if the patient thinks 2cm matters, and there's a 1cm measurement error, 
then you have to see 3cm before you can be confident that your observed effect is 
meaningful to the patient (their 2cm, plus the possibility of a 1cm error). Of course no-one 
ever does this, but this is important for the reasons you say. As you're aware, it's pretty rare 
for patients to ever be consulted in this stuff, so the idea of framing results in a context that's 
important to patients is the key point here, not the technicalities of how to do it.
Rod Whiteley
Many thanks for your input again on this. We have corrected the graph to better highlight 
that MDC and MCID are additive (rather than independent). We have also included the 
following – 
Although study B7 reports a larger average effect, most of the observed changes do not 
reach the threshold for clinical importance (MDC+MCID) and are unlikely to be meaningful to 
patients.  
Reviewer: 2
Comments to the Author
I commend the authors for addressing all of my concerns skillfully and satisfactorily. This 
editorial should aid clinicians and academics alike. This work provides a useful systematic 




Comments to the Author
Please see attached file
While some of my concerns from the first round of reviews have been addressed (mandatory
standard, wording on a priori registration, harmonization vs replication), many more have not 
been sufficiently addressed. My main concern is that this editorial does not bring much new 
to the table, except for the collection of four individually important (and quite well known) 
topics under an acronym. By bringing these topics together, we should aim for something 
more than to tell readers that these topics should be considered. I lack a sense of how to 
operationalize FAIR, to make it useful. While the evidence is clear for the individual topics 
that make up FAIR, there is no evidence- base for the usefulness of FAIR itself.
Many thanks for reviewing this. We agree that many components of FAIR are well known, 
but we have provided evidence within the editorial that these components continue to be 
overlooked by both clinicians and researchers. We have amended the last paragraph to 
acknowledge FAIR as a preliminary concept.  
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FAIR is presented as a preliminary concept to help clinicians disentangle true positive from 
potentially false positive claims within sports medicine.
I add here just a few specific comments:
1. In the section on False Positive Risk, I find the example to be confusing for the topic 
of this section. I’m not sure how this can be useful for readers to assess the elevated 
risk of false discovery. More information is needed to show readers how to use this.
We have amended the second paragraph of this section as below: 
FPR calculation is underpinned by Bayes’ Theorem, whereby information from two sources 
(the prior probability of treatment success AND the data from the experiment), are combined 
to provide a “posterior probability” of treatment success. When appraising experimental 
research, we can reverse this logic using the data to estimate the prior probability of treatment 
success; whilst being cognizant that a neutral prior (a 50:50 chance of treatment success), is 
perhaps the largest that can be legitimately assumed.2  For example, an experimental study 
(n=20 per group) reporting a large effect size (1.1) and a p-value of 0.049, corresponds to a 
prior probability of 97% - if we assume a FPR of 5%. Such an inflated prior suggests the 
experiment was potentially unnecessary (as the researcher was almost certain of treatment 
success at the study’s inception), OR that the FPR exceeds the set threshold (eg. 5%) and 
there is elevated risk of false discovery.  
2. In my original review, I asked why the authors do not mention confidence intervals. 
The section on Clinical Importance have been updated; however, the focus is on 
effect sizes. First, why effect sizes and not effect measures? You even criticize this 
yourselves (“as they are standard scores [...] their clinical context is limited”). Effect 
estimates of effect measures, with c nfidence intervals, convey clinical context, and 
clinically relevant interpretations. Second, the description of confidence intervals as 
providing “potential range of an effect” is not entirely fair, as confidence intervals 
reflect the precision in the estimates, which is an important piece of information not 
reflected in P-values.
Many thanks – we now amended this section: 
P-values do little to indicate the clinical importance of observed treatment effects. Effect 
measures are more intuitive, but standard scores (eg. standardized mean difference) don’t 
provide immediate clinical context. Therefore, legitimate clinical importance can only be 
determined by framing the difference in means (+ confidence intervals) with relevant Minimal 
Detectable Change (MDC) and Minimal Clinical Important Difference (MCID) thresholds. 
MDC represents ‘the amount of change (in the outcome) that must be observed before it is 
considered above the bounds of measurement error’; and MCID represents ‘the smallest 
change (in the outcome) that would be important to patients’. These thresholds are 
commonly overlooked, and a 2018 audit found that just 7% of orthopaedic researchers 
referred to MCID when determining treatment effects.5 
  
3. I do feel I have to return to the example in Figure 1. There is something funny going on in 
this example. Yes, there is not always agreement between a 95% CI and a 5% significance 
test; however, in this example, we have the mean of a continuous variable, for which you 
would need to be very creative in your choice of CI and test to achieve a 95% CI as that for 
A in Figure 1 and a P < 0.05 for the corresponding test. The lower limit of the CI is approx. -1 
cm, which in this case is quite far from the null effect of 0. Maybe this is a small point, but I’m 
left with the impression that there is something incorrect here.
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Many thanks – we have double checked the data from these studies and the error bars 
remain unchanged. However, we agree that such a large overlap may cause some 
confusion to readers, or may even be the result of a reporting error on the original 
publications. Therefore, we selected different data and amended Figure 1. 
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There is concern that a large proportion of scientific research is based on false positive, non-
replicable conclusions.1 As most experimental research in Sports Medicine is based on frequentist 
reasoning, p-values have been at the center of knowledge claims and new discoveries within this 
field. But many researchers and clinicians are unable to define or accurately interpret p-values. 
Common misconceptions are that p-values represent ‘the probability that the null hypothesis is 
true’ or ‘the probability that the hypothesis being tested is true.’2 In effect, p-values only quantify 
the chances of getting the observed data (on the assumption that the null hypothesis is true), and 
therefore cannot exclusively inform clinical decision making. This editorial presents FAIR: a 4-
item approach to help validate new discovery in sports medicine.  
1. False Positive Risk (FPR)
FPR is “the probability of observing a statistically significant p-value and declaring that an effect 
is real, when it is not.”2 Crucially, a study’s FPR can be high, even when the corresponding p-
values are low. In a systematic audit of high quality randomized controlled trials in sports 
physiotherapy, 18% of ‘statistically significant’ findings had a 50% chance of false discovery 
(claiming a treatment effect is real when it isn’t).3 
FPR calculation is underpinned by Bayes’ Theorem, whereby information from two sources (the 
prior probability of treatment success AND the data from the experiment), are combined to provide 
a “posterior probability” of treatment success. When appraising experimental research, we can 
reverse this logic using the data to estimate the prior probability of treatment success; whilst being 
cognizant that a neutral prior (a 50:50 chance of treatment success), is perhaps the largest that 
can be legitimately assumed.2  For example, an experimental study (n=20 per group) reporting a 
large effect size (1.1) and a p-value of 0.049, corresponds to a prior probability of 97% - if we 
assume a FPR of 5%. Such an inflated prior suggests the experiment was potentially unnecessary 
(as the researcher was almost certain of treatment success at the study’s inception), OR that the 
FPR exceeds the set threshold (eg. 5%) and there is elevated risk of false discovery.  
2. A priori registration 
Currently only 1 in 3 RCTs in sports physiotherapy are prospectively registered.3 A priori 
registration of clinical trials ensures that key study details, including primary outcomes, are made 
public prior to analysis. Unregistered trials carry a higher risk of false discovery, due to unplanned 
multiple testing, selected reporting and confirmation bias. Registration can help to control the 
‘degrees of freedom’ a researcher has when making small but important decisions regarding data 
analysis and reporting.4 The corollary is that positive conclusions from prospectively registered 
RCTs should hold most weight; with positive findings from unregistered studies considered as 
exploratory or even hypothesis generating. 
3. Clinical Importance 
P-values do little to indicate the clinical importance of observed treatment effects. Effect measures 
are more intuitive, but standard scores (eg. standardized mean difference) don’t provide 
immediate clinical context. Therefore, legitimate clinical importance can only be determined by 
framing the difference in means (+ confidence intervals) with relevant Minimal Detectable Change 
(MDC) and Minimal Clinical Important Difference (MCID) thresholds. MDC represents ‘the amount 
of change (in the outcome) that must be observed before it is considered above the bounds of 
measurement error’; and MCID represents ‘the smallest change (in the outcome) that would be 
important to patients’. These thresholds are commonly overlooked, and a 2018 audit found that 
just 7% of orthopaedic researchers referred to MCID when determining treatment effects.5 
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Figure 1 shows data from two experimental studies,6 7 each reporting statistically significant 
changes in ankle dorsiflexion post intervention (p<0.05). Despite this, the treatment effects 
observed in study A6 cannot be differentiated from measurement error. Although study B7 reports 
a larger average effect, most of the observed changes do not reach the threshold for clinical 
importance (MDC+MCID) and are unlikely to be meaningful to patients.  
Insert Figure 1 
Figure 1 footnote: 
Dots (and whiskers) represent mean change scores (95% CIs) 
Ankle dorsiflexion measured through a weight bearing lunge test (cm).; MDC = 1.9cm; MCID = 2cm
4. Replication 
The replication crisis is a ubiquitous and complex problem across all of science. Sports medicine 
has been slower to react compared to other fields of medicine; currently, the volume of research 
in this field which has been successfully corroborated through replication is unclear. FAIR reminds 
clinicians and researchers that independent replication underpins scientific discovery; and that it 
is presumptuous to conclude treatment effectiveness based on a single significant result.  
Summary
Time restraints and lack of training are cited as common barriers preventing clinicians from fully 
engaging in the evidence base. P-value thresholds (is p<0.05?) offer a fast but ultimately limited 
method for determining clinical effectiveness. Although there are many other aspects of trial 
design and reporting that can increase the risk of false discovery; FAIR is presented as a 
preliminary concept to help clinicians disentangle true positive from potentially false positive 
claims within sports medicine. 
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There is concern that a large proportion of scientific research is based on false positive, non-
replicable conclusions.1 As most experimental research in Sports Medicine is based on frequentist 
reasoning, p-values have been at the center of knowledge claims and new discoveries within this 
field. But many researchers and clinicians are unable to define or accurately interpret p-values. 
Common misconceptions are that p-values represent ‘the probability that the null hypothesis is 
true’ or ‘the probability that the hypothesis being tested is true.’2 In effect, p-values only quantify 
the chances of getting the observed data (on the assumption that the null hypothesis is true), and 
therefore cannot exclusively inform clinical decision making. This editorial presents FAIR: a 4-
item approach to help validate new discovery in sports medicine.  
1. False Positive Risk (FPR)
FPR is “the probability of observing a statistically significant p-value and declaring that an effect 
is real, when it is not.”2 Crucially, a study’s FPR can be high, even when the corresponding p-
values are low. In a systematic audit of high quality randomized controlled trials in sports 
physiotherapy, 18% of ‘statistically significant’ findings had a 50% chance of false discovery 
(claiming a treatment effect is real when it isn’t).3 
FPR calculation is underpinned by Bayes’ Theorem, whereby information from two sources (the 
prior probability of treatment success AND the data from the experiment), are combined to provide 
a “posterior probability” of treatment success. When appraising experimental research, we can 
reverse this logic using the data to estimate the prior probability of treatment success; whilst being 
cognizant that a neutral prior (a 50:50 chance of treatment success), is perhaps the largest that 
can be legitimately assumed.2  For example, an experimental study (n=20 per group) reporting a 
large effect size (1.1) and a p-value of 0.049, corresponds to a prior probability of 97% - if we 
assume a FPR of 5%. Such an inflated prior suggests the experiment was potentially unnecessary 
(as the researcher was almost certain of treatment success at the study’s inception), OR that the 
FPR exceeds the set threshold (eg. 5%) and there is elevated risk of false discovery.  
2. A priori registration 
Currently only 1 in 3 RCTs in sports physiotherapy are prospectively registered.3 A priori 
registration of clinical trials ensures that key study details, including primary outcomes, are made 
public prior to analysis. Unregistered trials carry a higher risk of false discovery, due to unplanned 
multiple testing, selected reporting and confirmation bias. Registration can help to control the 
‘degrees of freedom’ a researcher has when making small but important decisions regarding data 
analysis and reporting.4 The corollary is that positive conclusions from prospectively registered 
RCTs should hold most weight; with positive findings from unregistered studies considered as 
exploratory or even hypothesis generating. 
3. Clinical Importance 
P-values do little to indicate the clinical importance of observed treatment effects. Effect measures 
are more intuitive, but standard scores (eg. standardized mean difference) don’t provide 
immediate clinical context. Therefore, legitimate clinical importance can only be determined by 
framing the difference in means (+ confidence intervals) with relevant Minimal Detectable Change 
(MDC) and Minimal Clinical Important Difference (MCID) thresholds. MDC represents ‘the amount 
of change (in the outcome) that must be observed before it is considered above the bounds of 
measurement error’; and MCID represents ‘the smallest change (in the outcome) that would be 
important to patients’. These thresholds are commonly overlooked, and a 2018 audit found that 
just 7% of orthopaedic researchers referred to MCID when determining treatment effects.5 
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Figure 1 shows data from two experimental studies,6 7 each reporting statistically significant 
changes in ankle dorsiflexion post intervention (p<0.05). Despite this, the treatment effects 
observed in study A6 cannot be differentiated from measurement error. Although study B7 reports 
a larger average effect, most of the observed changes do not reach the threshold for clinical 
importance (MDC+MCID) and are unlikely to be meaningful to patients.  
Insert Figure 1 
Figure 1 footnote: 
Dots (and whiskers) represent mean change scores (95% CIs) 
Ankle dorsiflexion measured through a weight bearing lunge test (cm).; MDC = 1.9cm; MCID = 2cm
4. Replication 
The replication crisis is a ubiquitous and complex problem across all of science. Sports medicine 
has been slower to react compared to other fields of medicine; currently, the volume of research 
in this field which has been successfully corroborated through replication is unclear. FAIR reminds 
clinicians and researchers that independent replication underpins scientific discovery; and that it 
is presumptuous to conclude treatment effectiveness based on a single significant result.  
Summary
Time restraints and lack of training are cited as common barriers preventing clinicians from fully 
engaging in the evidence base. P-value thresholds (is p<0.05?) offer a fast but ultimately limited 
method for determining clinical effectiveness. Although there are many other aspects of trial 
design and reporting that can increase the risk of false discovery; FAIR is presented as a 
preliminary concept to help clinicians disentangle true positive from potentially false positive 
claims within sports medicine. 
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Figure 1 footnote: 
Dots (and whiskers) represent mean change scores (95% CIs) 
Ankle dorsiflexion measured through a weight bearing lunge test (cm); MDC = 1.9cm; MCID = 2cm 
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